The finding that human factor Vlll (NIII) inhibitor antibodies with C2 domain epitopes interfere with the binding of Nlll to phosphatidylserine (PS) suggested that this is the mechanism by which they inactivate NIII. We constructed a recombinant C2 domain polypeptide and demonstrated that it bound to all six human inhibitors with Nlll light chain specificity. Thus, some antibodies within the polyclonal anti-light chain population require only amino acids within C2 for binding. Recombinant C2 also partially or completely neutralized the inhibitor titer of these plasmas, demonstrating that anti-C2 antibodies inhibit Nlll activity. lmmunoblotting of a series of C2 deletion polypeptides, expressed in Escherichia coli, with inhibitor plasmas showed that the epitopes for human inhibitors consist of a common core of amino acid residues 2248 through 2312 with differing extensions for individual inhibitors. The epitope of inhibitory monoclonal antibody (MoAb) ESH8 was localized to residues 2248 through T HE PLASMA glycoprotein factor VIII' (NIII) is an essential component of the intrinsic pathway of blood coagulation, and it is absent or dysfunctional in individuals with hemophilia A. In the circulation, NI11 is stabilized by the formation of a complex with von Willebrand factor (vWF),' from which it is released after proteolytic activation by thrombin? Activated N I 1 1 serves as a cofactor, along with calcium and phospholipid on a membrane surface, for factor IXa in the proteolytic activation of factor X.3*4
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The protein sequence of N I 1 1 was deduced by cDNA cloning: it contains two series of homologous repeats and a unique sequence in the order Al-A2-B-A3-Cl-C2, which together comprise a 265-kD p~lypeptide.~ The N I 1 1 protein is cleaved intracellularly to form a heavy chain composed of the Al, A2, and B domains and a light chain composed of the A3, Cl, and C2
The secreted heterodimer is proteolytically activated by thrombin to a heterotrimer consisting of the A1 and A2 domains and the light chain, all of which are required for activity.' The B domain is nones~ential~,~ and is lost after activation."
The NI11 light chain binds to vWF at a site that includes residues from the C2 domain'' and for which the presence of amino acid residues 1649 through 1689 appears to be e~sential.~.'~.'~ The light chain also functions in the binding of NI11 to plateletsi4 and to the negatively charged phospholipid, phosphatidylserine (PS). 15 A binding site for the latter was localized to amino acid residues 2303 through 2332 of the C2 domain.I6 FVIII binds specifically to vesicles containing PS by a stereoselective interaction with the ionic head group, 0-phospho-L-serine." Factor V also binds to PS-containing membranes, but it does not compete with NI11 for vesicle or platelet binding.14 The relationship between the phospholipid and the platelet-binding sites of the two factors is, thus, unknown. 2285. Three human antibodies and anti-C2 MoAb NMC-VIIII 5 bound to a synthetic peptide consisting of amino acids 2303 through 2332, a PS-binding site, but MoAb ESHI did not. These antibodies also inhibited the binding of Nlll to synthetic phospholipid membranes of PS and phosphatidylcholine, confirming that the blocked epitopes contribute to membrane binding as well as binding to PS. In contrast, MoAb ESH8 did not inhibit binding. As the maximal function of activated Nlll in the intrinsic factor Xase complex requires its binding to a phospholipid membrane, we propose that Nlll inhibition by anti-C2 antibodies is related to the overlap of their epitopes with the PS-binding site. MoAb ESHI did not inhibit Nlll binding to PS-containing membranes, suggesting the existence of a second mechanism of Nlll inhibition by anti42 antibodies.
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mately 25% of hemophilia A patients is the development of IgG antibodies, which inhibit fVIII activity (inhibitors).18 Two common epitopes for these antibodies are contained within the NI11 A2 and C2 domain^.'^**^ Those inhibitors that bind to C2 also prevent the binding of NI11 to PS, suggesting that this effect is responsible for their inactivation of fVIII.2L Conversely, binding to phospholipid protects N I 1 1 from inactivation by some inhibitors."
As the mechanism for this effect has not been explored, we undertook a more precise localization of inhibitor epitopes within the C2 domain to understand how inhibitors may prevent phospholipid binding of N I 1 1 and to determine whether this is the only mechanism of inhibition. We have also constructed a soluble, recombinant C2 domain polypeptide for use in inhibitor neutralization assays that can be used to directly determine if anti-C2 antibodies are inhibitors of N I 1 1 activity.
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MATERIALS AND METHODS
Monoclonal and human anti-jVl11 antibodies. Sources of immunoassay reagents were as follows: monoclonal antibodies (MoAbs) ESH8 and ESH4,23 American Diagnostica (Greenwich, CT); IgG of MoAb antihuman IgG4 from clone SK-44, ICN Biomedicals (Costa Mesa, CA); biotinylated goat antihuman IgG, Kierkegaard and Perry (Gaithersburg, MD); streptavidin-alkaline phosphatase, Life Technologies (Gaithersburg, MD). MoAb J16D-9, raised against W111 peptide 2318 through 2332, was provided by Dr Carol Fulcher (Scripps Clinic and Research Foundation, La Jolla, CA). MoAb 41 3 epitope localization to NI11 amino acid residues 373 through 606 and IgG purification and biotinylation were previously de~cribed.'~ The epitopes of five of the human antibodies and MoAb NMC-VIII/5 were previously determined by immunoblotting assays to lie within the human antibody MU were determined in the present study. Inhibitor CC also bound to epitopes within the amino-terminal half of the A2 domain by imm~noblotting,'~~'~ and RI bound to the A2 domain only in an immunoprecipitation assay. 24 The human antibodies, identified by the same initials used in previous publications, were shown to prevent the binding of N I 1 1 to PS by enzyme-linked immunosorbent assay (ELISA)." The characterization of MoAb NMC-VIIV5 was previously described.2s All the antibodies used in our study are inhibitors of N I 1 1 activity, and the inhibitor titers, as determined in the Bethesda assayz6 for each purified IgG, are shown in Table 1 .
Inhibitor IgG was purified by affinity chromatography on protein G Sepharose (Gammabind G Plus; PharmaciaLKB, Uppsala, Sweden), and NI11 light chain was purified from plasma WIII, as described." The purity of the light chain was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and a heavy chain-specific ELISA using two MoAbs with different epitopes to be greater than 95% pure. It was coupled to Affi-Prep I O (BioRad, Hercules, CA) at 344 p g h L resin. Inhibitor IgG (100 to 200 Bethesda units [BU] ) was loaded onto the column in 50 mmoVL Tris pH 7.4, 500 m m o w NaCI, 5 mmol/L CaC1,. The bound IgG was eluted in 50 mmol/L Tris pH 7.5, 500 mmoVL MgClz, 5 mmoVL CaC12, 50% ethylene glycol, and its concentration was determined by ELISA using two MoAbs with different human IgG epitopes compared with a standard of normal human IgG. The yields of active inhibitor (BU) and light chain-specific IgG were 34% to 42% and 1.3% to 4.2%, respectively, for three inhibitor IgGs purified. The specific activity (BU/mg) increased fourfold to 30-fold after affinity purification.
Immunoblotting and immunoprecipitation assays. The details for immunoblotting and immunoprecipitation have been described.'" Briefly, the binding of human inhibitor plasma to deletion polypep-C2 domain,19.20.Z4.2S The epitopes of MoAbs ESH8 and ESH4 and tide derivatives of NI11 by immunoblotting was detected with MoAb anti-human IgG4 SK-44, biotinylated goat antimouse IgG, and streptavidin-alkaline phosphatase. For MoAb immunoblotting, the SK-44 was omitted. In some cases, biotinylated goat antihuman IgG was used to detect inhibitor binding directly. Biotinylated MoAb ESH8 was used directly for immunoblotting. A colorimetric substrate was used to assay bound phosphatase. For immunoprecipitation assays, inhibitor plasma or IgG was incubated sequentially with a iSS-methionine-labeled C2 domain polypeptide and protein G Sepharose (PharmaciaLKB). The immobilized immune complexes were washed, separated from protein G by denaturation, and analyzed by polyacrylamide-SDS discontinuous gel electrophoresis and autoradiography.
Construction of derivatives of the C2 domain. An fVIII cDNA clone was used to construct series of amino-or carboxyl-terminal deletions of the C2 domain for expression in Escherichia coli as described." The C2 derivatives were cloned into an expression plasmid in which unique restriction endonuclease sites bordered C2, so that C2 could be removed and replaced with the mutant C2 domains.
The C2 domain cDNA was also amplified by the DNA polymerase chain reaction with a 5' primer that matched 24 bases at the 5' end of the coding sequence and contained an Nhe I restriction site. The 3' primer of 18 bases matched a sequence from the parent plasmid downstream of a HindIII site, so that 14 bp of 3' W111 noncoding sequence were included at the end of C2. The resulting DNA fragment was digested with NheI and HindIII and cloned into the same sites of plasmid pSV7d120D3-D4-D5/SF2, provided by Chiron Corp (Emeryville, CA), for fusion to the prepro-peptide of tissue plasminogen activator.** The prepro-C2 cDNA was subcloned into the baculovirus transfer vector pVL941, provided by Dr Max Summers (Texas A&M University, Austin), by a polymerase chain reaction procedure that introduced new restriction sites at the 5' and 3' ends. The resulting plasmid and baculovirus Autographa californica DNA were used to cotransfect Spodopteru frugiperda Sf9 insect cells. A recombinant baculovirus encoding C2 was purified as described,'"." and C2 expression was confirmed by immunoblotting with MoAb ESH8. All modified DNA sequences were verified by sequencing using the dideoxy chain termination method.
Preparation of extracts containing derivatives of the C2 domain. The amino-terminal, carboxyl-terminal, and internal deletions of C2 were produced in Escherichia coli, and extracts were prepared as described."~*" The presence of the correct NI11 polypeptide in each extract was confirmed by immunoblotting analysis with MoAbs J16D-9 or ESH8 with C2 domain epitopes 2316 through 2332 and 2248 through 2285, respectively. The concentration of the individual polypeptides varied by twofold to threefold at most. The C2 domain polypeptide was produced in Sf9 insect cells as described for the A2 domain. 24 The growth medium containing the secreted C2 was subjected to low-speed centrifugation to remove intact cells and at 8,OOOg for 10 minutes to remove cellular fragments. It was used without further purification.
Synthetic peptides. Peptides were synthesized on a 9050 Milligen synthesizer (Millipore, Bedford, MA) by the 9-fluorenylmethoxycarbonyl method and pentaphenylfluoro ester activation chemistry, and they were purified by high performance liquid chromatography on a C18 column (Waters, Marlboro, MA). Composition analysis of peptides demonstrated that the average deviation of any amino acid from the expected value was not greater than 10%. Peptide 2303 through 2332 and a randomized version of the same sequence were dissolved in 60% acetonitrile, diluted with H 2 0 to 10% acetonitrile at 0.6 to 0.7 mmoVL peptide, and stored at 4°C.
ELISA for determination of P I U binding to phosphatidylserine or inhibitor binding to synthetic peptides. The solid phase ELISA for fVIII binding to PS (Sigma Chemical CO, St Louis, MO) was For personal use only. on January 4, 2018. by guest www.bloodjournal.org From FACTOR Vlll ANTI-C2 INHIBITOR ANTIBODIES 1813 performed as described by Bloom3' with the following modifications. PS solutions at 5 pg/mL in methanol were added to Immulon I microtiter plates (Dynatech, Chantilly, VA) and air dried. All buffers contained 20 mmoVL Tris pH 7.5. For blocking and dilution of NI11 or IgG, Tris + 0.5% gelatin (BioRad) was used, and for washes, Tris + 0.05% Tween 20 (Sigma) was used. The binding of recombinant fVlII (2,870 U/mg; Baxter Healthcare Corp. Duarte, CA) was detected by incubation with MoAb 413-biotin, 0.33 pg/mL, followed by streptavidin-alkaline phosphatase. Bound phosphatase activity was measured colorimetrically in 0.1 m o m glycine pH 9.4, 1 mmoU L MgCI2, 2 mmom ZnCIZ with 4 mg/mL p-nitrophenylphosphate (Sigma). Color development was measured at 405 nm in a Dynatech MR600 microtiter plate reader.
Microtiter plates were coated with peptide at 5 pg/mL in 0.1 m m o n sodium carbonate buffer, pH 9.6. Subsequent steps were performed in Tris-buffered saline (TBS), 1% gelatin. IgG binding was detected with biotinylated goat-antihuman IgG or biotinylated goat-antimouse IgG, as required, and streptavidin-alkaline phosphatase as above. Washes were performed with TBS, 0.1% Tween.
Flow cytomerry assay for evaluafing factor binding to syntheric membranes. Recombinant NIII, a gift from Debra Pittman, Genetics Institute (Boston, MA), was labeled with fluorescein-maleimide as previously de~cribed.~',~' The protein concentration of labeled W111 was determined using a Micro-BCA Assay (Pierce, Rockford, IL) using bovine albumin as a standard. Small unilamellar vesicles consisting of PS/phosphatidylcholine (PC)/cholesterol (15/85/20) were synthesized by sonication as previously de~cribed,'~ except that sonication was in a bath sonicator (Laboratory Supplies CO, Hicksville, NY). Vesicles were used fresh, or l-mL aliquots were quick-frozen in liquid nitrogen, stored at -8O"C, and thawed at 37°C. Storage at 4°C before incubation with microspheres did not exceed 1 day. Glass microspheres of 1.6 pm nominal diameter (Duke Scientific, Palo Alto, CA) were cleaned, size-restricted, and covered with a phospholipid bilayer as previously described." Membranes supported by glass microspheres were washed three times in 0.15 mol/ L NaCI, 0.02 m o m Tris-HC1, 0.1% defatted bovine albumin, 10 pmol/L egg PC as sonicated vesicles: stored at 4°C; and used within 8 hours of synthesis.
Fluorescein-fVIII (4 nmol/L) was incubated with inhibitor antibodies for 1 hour at room temperature, the mixture was added to lipospheres for an additional 10 minutes, and membrane-bound NI11 was measured by flow cytometry. This procedure was performed on 25-pL aliquots of 100-pL samples with an approximate liposphere concentration of 1 X 106/mL using an EPICS-Profile I1 flow cytometer (Coulter, Miami, FL). Data acquisition was triggered by forward light scatter with all photomultipliers in the log mode. Noise was reduced during analysis by eliminating events with forward and side scatter values different from those characteristic of the lipospheres. Mean log fluorescence was converted to linear fluorescence for values depicted in the figures. Only experiments in which the fluorescence histogram indicated a log normal distribution, as judged by inspection, were analyzed quantitatively, Flow cytometry experiments were performed in 0.14 mom NaCI, 0.02 mom Trizma-HC1, 0.5 mmoVL CaCI2, 0.1% bovine albumin, and 0.001% Tween 80 pH 7.5.
RESULTS
Assay of inhibitor neutralization by the C2 domain polypeptide. To determine if the human anti-C2 antibodies identified in immunoblotting assays" and described in Table  1 Plasmas from six patients with antibodies that bound to C2 by immunoblotting assay were used for inhibitor neutralization assays. The characteristics of each are described in Materials and Methods and in Table 1 . Table 1 . Plasmas MR, F, and MU were greater than 95%, 70%, and 17% neutralized, respectively, by C2 (Fig IA) , and the other human antibodies were 20% to 37% neutralized. These results were reproducible for MR and MU, but in a subsequent experiment, inhibitor F was greater than 95% neutralized by the light chain. The ability of inhibitors to be neutralized by C2 shows that their binding to native NI11 is competed by C2. The complete (>95%) neutralization of MoAb anti-C2 controls ESH8 (Fig 1B) and NMC-VIIV5 suggests that the partial neutralization of some human antibodies by the C2 polypeptide is not due to an abnormal C2 conformation. JM, a human antibody that was completely neutralized by the A2 domain in previous experimentsz7 was not neutralized by C2 (Fig 1A) . MoAb ESH4 was not efficiently neutralized (about 15%) by C2, and its inhibitor titer was only 142 BU/ mg IgG. As these properties may be due to its low affinity for C2, it was not further characterized.
We interpret the partial neutralization results for MP, RI, CC, and MU by C2 to mean that for these plasmas antLC2 antibodies are not the only inhibitors. Thus, they were further tested for neutralization either by a recombinant A2 domain polypeptide previously described" or by purified recombinant W111 light chain. Neutralization assays with the same dilution of each inhibitor and increasing concentrations of the different polypeptides were performed simultaneously. MP and MU, which were partially neutralized by C2 but not by A2 (less than 5%), were greater-than-95% neutralized by the light chain. RI, however, required A2 and the light chain for full neutralization, but it was also 34% neutralized by C2. The properties of MP, RI, F, and MU suggest that an anti-light chain antibody in addition to the anti-C2 antibody also contributes to the inhibitor titer. CC was partially neutralized either by A2 (78%) or by C2 (37%), and when both polypeptides were added at saturating concentrations, it was greater-than-95% neutralized (not shown). An alternate explanation for the partial neutralization of some antibodies by C2 and more extensive neutralization by the light chain is that the separate C2 polypeptide does not have the same properties as C2 does when it is synthesized as part of the light chain. When MR was assayed either with C2 or with the light chain in the same experiment (Fig lB) , 50% neutralization required approximately equimolar concentrations of each polypeptide. These results suggest that C2 is correctly folded during its biosynthesis in Sf9 cells.
MoAb ESH8, however, was 50% neutralized by 0.2 nmol/ L C2 and by 1.5 nmol/L light chain, indicating that its epitope may be more accessible in the isolated C2 domain (Fig   1B) .
Localization of epitopes for human anti-jVII1 antibodies and MoAh ESH8 within theJVIII C2 domain. The growth medium from cells infected with the baculovirus encoding recombinant C2 and labeled with %-methionine 48 hours postinfection was incubated with inhibitor IgG, immunoprecipitated, and analyzed by gel electrophoresis and autoradiography. The human inhibitors listed in Table 1 and MoAb ESH8 all bound to C2 (Fig 2, lanes 2 through 8) . while a control without antibody was negative (Fig 2, lane 1) demonstrate that the binding of some antibodies within the polyclonal anti-light chain population requires only amino acids within C2.
To further localize the epitopes of the anti-C2 domain antibodies studied above relative to the PS-binding site within amino acid residues 2303 through 2332, deletions of C2 were constructed from a plasmid that contained cDNAencoding WIII amino acid residues 1974 through 2332, including the carboxyl-terminal 47 residues of the A3 domain and the Cl and C2 domains (fragment L4I9). This strategy was used because deletion of the C2 domain from fragment L4 to generate fragment L4.2 abolished human anti-W111 antibody binding in previous immunoblotting assays.*" In addition, fusion of the C2 deletions to full-length Cl allows the production of polypeptides of at least 18 kD, which can be analyzed readily by immunoblotting.
In our previous immunoblotting experiments, inhibitors CC, MP, F, RI, and MR bound to fragment L4.1, in which 80% of the Cl domain was deleted, but not to fragment L4.2, in which amino acid residues 2178 through 2332 (96%) of C2 were deleted, demonstrating that there was no crossreaction of these antibodies with Cl ."'.*' The epitopes were further localized by immunoblotting of each antibody with the C2 deletion polypeptides represented graphically in Fig  3. Inhibitor CC bound to C2 amino-terminal deletion polypeptides L4.4-L4.6 but not to longer deletions (Fig 4A) , and it bound only to the carboxy-terminal deletions L4.13-L4. 16 (Fig 4B) . A negative control (-) consisting of a bacterial extract from cells containing the parental plasmid with no The results for all inhibitors tested are summarized in Table 2 .
Assuming that polypeptides that do not bind to a particular antibody lack those amino acids involved directly in antibody binding or in the formation of the correct conformation of the epitope, the mapping data suggest that antLC2 antibodies from CC bind to an epitope within C2 amino acids 22 18 through 23 12. The epitopes were determined similarly for other human and MoAbs, as summarized in Table 2 . Six different overlapping regions in which the amino-or carboxyl-termini varied were identified as epitopes. The human antibodies and MoAb NMC-VIII15's epitopes require the presence of a common region including amino acids 2248 through 23 12, an area that overlaps a PS-binding site, 2303 through 2332." 
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The extent of each deletion polypeptide, preceeded by an L, is shown in Fig 3. There were no detectable bands in the negative control of an E colistrain containing a plasmid without an Nlll insert or in responses rated as "-". None of the human inhibitors bound to additional deletion polypeptides L4.10-L4.12, L4.18, L4.3, and L4.19. ESH8 did not bind to polypeptides L4.9-L4.12 and L4.20. The epitopes are given in mature Nlll amino acid residue numbers. The C2 domain encompasses residues 2173 through 2332. The epitope of MoAb NMC-VIII/5 was previously determined using the same deletion polypeptides to lie within residues 2170 through 2327F5
Use of a synthetic peptide to determine if the PS-binding site and the inhibitor epitopes overlap. A synthetic peptide containing amino acid residues 2303 through 2332 was previously shown to inhibit NI11 binding to PS by ELISA,I6 and our epitope localization studies described above suggested that the residues 2303 through 23 12 are also contained within the C2 domain inhibitor epitope. Figure 6A shows the results of an experiment in which MoAb ESH8 was compared with MU and MR for the ability to inhibit NI11 binding to PS. MU and MR IgG prevented NI11 binding by greater than 90% at 2 pg/mL and 34 pcLg/mL total IgG, respectively. These IgG concentrations correspond to approximately 2 BU/mL in each case. MoAb ESH8 had no effect up to 50 pg/mL, and in a separate experiment (not shown), there was only 30% inhibition at 100 pg/mL. At the latter concentration, the Bethesda titer was 315 U/mL, suggesting that this weak inhibitory effect on PS binding is not responsible for the substantial effect on NI11 activity seen in a clotting assay.
To verify these findings for phospholipid membranes, the effects of monoclonal and human antibodies on NIII binding to P S R membranes was tested. The binding of fluoresceinlabeled fVII to P S R membranes supported by glass microspheres in the presence of increasing antibody concentrations was measured by flow cytometry (Fig 6B) . The h4R, MU, and F light chain-specific IgG described above and MoAb NMC-W 5 reduced binding by 90% to loo%, whereas MoAb ESH8 had no significant effect.
DISCUSSION
The intrinsic factor Xase complex (fVIIIa, factor E a , and factor X) requires the presence of a cell membrane or synthetic phospholipid vesicles for maximal activity! The IgG from hemophilia A patients with anti-NIII C2 domain antibodies and fVIII inhibitor activity prevented the binding of fVIII to PS in vitro, suggesting indirectly that this property was responsible for their inhibition of fVIII.2' Because most inhibitor plasmas contain multiple anti-fVIII antibodies," the finding that anti-C2 MoAb NMC-VIIUS also inhibited NIII/PS binding demonstrated that the inhibitor activity of some antibodies can be accounted for in this way.25 In this study, the anti-fVIII activity of antibody MR was completely neutralized by a soluble, recombinant C2 domain polypeptide, confirming that the inhibitory activity of some human anti-NIII antibodies is entirely due to inhibition of fVIII functions located within the C2 domain. The inhibitor titer of the five other human antibodies tested was partially neutralized (17% to 70%) by C2.
In previous experiments, we used immobilized 100% PS as a model for W111 membrane binding.*' To show that anti-C2 antibodies also have an effect on fVIII binding to more complex membranes, we tested their ability to inhibit N I 1 1 binding to PSPC membranes supported by glass microspheres. MoAb NMC-VIIUS and affinity-purified human inhibitors MR, MU, and F reduced fVIII binding by at least 85%, whereas MoAb ESHS had no inhibitory effect. A C2 synthetic peptide 2304 through 2324 was reported to inhibit fVIII binding to PSPC membranes in a similar assay. 33 These results confirmed that a membrane-binding site resides in the C2 domain and suggested that fVIII binding to immo-
bilized PS is a useful model for membrane binding. It has recently been proposed for factor V34-36 that PS binding may represent the first step in a multistep process of its binding to a membrane, and that a later step involving the A3 domain leads to high affinity binding. As the C2 domain of factor V is proposed to mediate PS binding:' a similar mechanism might exist for fVIII. If this is the case, human inhibitor antibodies would prevent the first interaction of fVIII with the membrane.
To determine the mechanism for antibody inhibition of fVIII/PS binding, we localized the epitopes for six human and one monoclonal anti-C2 antibodies. A common region required for the binding of each antibody consists of amino acid residues 2248 through 2312. Some antibodies also required regions to one or both sides. This does not imply, however, that each antibody is binding to the same residues within this region. The human inhibitor epitopes defined by immunoblotting appeared to share a region of 9 to 24 amino acid residues, with a PS-binding site localized to residues 2303 through 2332.16 Human antibodies MU, MR. and F and MoAb NMC-VIIUS did, in fact, bind directly to immobilized synthetic peptide 2303 through 2332, but MoAb ESH8 (epitope 2248 through 2285) binding was threefold lower. We propose a model in which overlap of the inhibitor epitope with at least part of the PS-binding site is a requirement for inhibition of fVIII/PS binding by anti-C2 antibodies. The carboxyl-terminus of the ESH8 epitope is located 18 residues away from the PS site in the linear protein sequence, and our results suggest that this region is not physically contiguous to the PS site in the three-dimensional structure of C2.
The inhibitor activity of human antibodies MP, MR, RI, CC, F, and MU was 283% neutralized by the A2 domain andor the light chain. In these patients, anti-AI or anti-B domain antibodies, if they exist, do not contribute to the overall inhibitor titer. The inhibitor titer of CC was partially neutralized by both A2 and C2 and completely neutralized by both of them, whereas RI required A2 and the light chain for complete neutralization. The MP, RI, F, and MU inhibitor titers were partially neutralized by C2 but were greater-thanFor personal use only. on January 4, 2018. by guest www.bloodjournal.org From 95% neutralized by the light chain, As neutralization by C2 of these antibodies reached a plateau beyond which further increases in C2 did not give increased neutralization, we interpret this result to mean that additional antibodies with fVIII inhibitor activity bind to light chain epitopes outside the C2 domain. The presence of such antibodies was also postulated in an earlier study from our laboratory." Direct binding assays of these human antibodies to the A3 or C l domains or to the light chain acidic region must be performed to confirm this hypothesis. Neutralization of human W111 inhibitor antibodies by several recombinant NI11 polypeptides has allowed us to determine that one to three different antibodies are responsible for the inhibitor titer in the patients that we have tested. This is consistent with our previous finding that most inhibitor plasmas contain multiple antifVIII antibodies, as measured in immunoprecipitation assay^.'^.^'
In contrast to the human inhibitors, MoAb ESH8 did not prevent W111 binding to PS, membrane-coated microspheres, or VWF.'' In addition, MoAb ESH8 inhibits NI11 activity efficiently only when it is complexed with vWF (unpublished results, November 1994). The mechanism of this inhibition is the subject of an ongoing investigation. However, it is clear that the effect of MoAb ESH8 is different from that of the human inhibitors tested, which compete with vWF for N I 1 1 binding." An anti-factor V monoclonal antibody analogous to MoAb ESH8 has been de~cribed.~' This antibody, 6A5, recognizes an epitope localized to the central region of the factor V C2 domain, and it does not inhibit factor V binding to immobilized PS. As these antibodies are inhibitors of their respective coagulation factors, it is likely that the central region of both C2 domains is important for their procoagulant activity.
